Table of Contents
The Affordable Care Act has created an upswing in the number of patients entering the US healthcare system, boosting the volume of routine and specialized testing performed in laboratories. This market insight analyzes the instrumentation and reagent segment activity within the US hemostasis market. Key trends and a comparative analysis between the installed base trends of 2012 and 2013 are provided for hospitals, blood banks, independent/reference labs, clinics/physician office laboratories (POLs), and public health institutes. A SWOT analyses and market share for the main leading vendors (e.g., Siemens/Sysmex, Diagnostica Stago, and Instrumentation Laboratories) have been studied. The base year is 2013 and forecasts span 2014 to 2016.
•The US hemostasis market was valued at $ x million in 2013 and is expected to reach $ x million in 2016.
•The compound annual growth rate (CAGR) for this period is x %.
•The Affordable Care Act (ACA) has boosted the number of patients using the healthcare system, which, in turn, has increased demand within the reagent market.
•Laboratory and hospital consolidation has caused the number of instruments per site to increase thus slowing down the sale of analyzers.
•Physician office erosion has resulted in a decreased customer base for the sale of low throughput analyzers.
CEO 360 Perspective
Blood banks and long term care (LTC) facilities look opportunistic considering fear of consolidation is mostly nonexistent in these customer segments.
Reference laboratories have turned towards volume-based testing to keep revenue flowing. Hence, high throughput analyzers find their placement in independent/reference laboratories.
In 2012–2013, the number of instruments per site in hospitals increased as a result of a heavy merger and acquisition (M&A) trend among hospitals.
Most physician offices are being acquired by hospital labs, which leads to client-base erosion that negatively affects manufacturers of small volume analyzers.
•The market can be segmented by analyzers and reagents. This does not include point of care testing (POCT).
•This research service covers only fully-automated analyzers.
•Key vendors are Sysmex/Siemens, Diagnostica Stago, and Instrumentation Laboratory.
•Includes analysis of only Clinical Laboratory Improvement Amendments (CLIA)-certified labs.
Comparative Analysis of 2012 and 2013 Trends in Hemostasis
The number of instruments per site in hospitals increased, mostly because several hospitals experienced a heavy M&A trend, hence the number of beds increased as facilities converged. In fact, the number of hospitals has declined since 2010 causing a heavy market contraction. Hospitals are therefore focused on high volume analyzers.
Please refer to the next slide for hospital stats.
In 2013, laboratory consolidation peaked. LabCorp, Quest Diagnostics, and Sonic Healthcare acquired new centers in the United States contributing to the upswing in number of instruments per site. In certain laboratory sites, instrument utilization had not been high. As laboratories consolidate, analyzers with a high–mid volume throughput are more in demand than medium–low volume analyzers. To cope with the numerous effects of the US healthcare reform, reference laboratories have turned towards volume-based testing to keep revenue flowing. Hence, high throughput analyzers find their placements in independent/reference laboratories.
Plasma testing is increasingly occurring in blood banks to support the safe transfusion of blood from the donor. Blood banks mostly house a medium-volume analyzer.
Public Health Institutes and LTC Facilities
LTC and public health institutes attract more and more investments as the market continues to grow. This market is not affected by consolidation.
Most physician offices are being acquired by hospital labs, which leads to client-base erosion that negatively affects manufacturers of small volume analyzers. Please refer to the next slide for statistics on percentage of physician offices year on year.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs). The report includes analysis ...
This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs). The report includes analysis of ...
Complete report $11,500. DataPack (test volumes, sales forecasts, supplier shares) $7,500. Summary This comprehensive report contains 306 pages, 59 tables, and is designed to help current suppliers ...